In SCLC however where BRCA mutations are rare (1–3.5% [9, 43]), we have previously shown that resistance to PARP inhibition to be correlated to activation of the PI3K/mTOR pathway [5]. This evidence concerns the gene MTOR and small cell lung carcinoma.